INCA Trial
INCA is a multicentre, randomised, phase II trial comparing IO-R-CVP with Gem-R-CVP in the first line treatment of patients with DLBCL who are not fit for anthracycline-containing chemotherapy. 132 patients will be randomised to receive either IO-R-CVP or Gem-R-CVP. Samples collected for trial: 7ml EDTA blood sample taken at baseline; Formalin fixed paraffin embedded tumour block - both sent to HMDS, Leeds. Blood serum sample (4.9ml) taken at Baseline (between day -14 pre registration and day 1 pre-treatment), Cycle 1 day 3 (+/- 1 day), Cycle 1 day 8 (+/-1 day) and Cycle 2 day 1 (-1 day) to be sent to Cancer Research UK Manchester Institute, Macclesfield.
Existing samples:
- Malignant lymphoma (disorder)
Contact Information
- Email:
- ctc.inca@ucl.ac.uk
- Address:
-
CR UK & UCL Cancer Trials Centre
90 Tottenham Court Road
London
Greater London
W1T 4TJ
England
Annual Statistics
| Year | Access Requests Received | Access Requests Approved | ||||
|---|---|---|---|---|---|---|
| Internal | External | Commercial | Internal | External | Commercial | |
| 2015 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2016 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2017 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2018 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2019 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2020 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2021 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2022 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2023 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2024 | N/A | N/A | N/A | N/A | N/A | N/A |
| 2025 | N/A | N/A | N/A | N/A | N/A | N/A |